Company intelligence / Profile preview

Convelo Therapeutics

Cleveland, Ohio, United Statesconvelotx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Convelo has identified two promising drug candidates (CVL-1001 and CVL-2001) that promote remyelination in preclinical models. The company is in final stages of safety studies in large animals and preparing for regulatory applications to advance to clinical trials.

Therapeutic areas: OtherNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

CVL-1001

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Genentech

Beyond the preview

Go deeper on Convelo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Convelo Therapeutics.

Explore the full profile